Locally advanced or metastatic pancreatic neoplasm with pathogenetic (C5) or possibly pathogenetic (C4) mutation of PALB2 found at the somatic or germinal level.
Conditions
Brief summary
Objective response rate (ORR), defined as the percentage of patients with response of either CR or PR.
Detailed description
Assessment of PFS (progression-free survival), DOR (duration of response), DCR (disease control rate), OS (overall survival), safety and tolerability of treatment. Furthermore, the quality of life will be assessed through the EORTC QLQ-C30 questionnaire.
Interventions
DRUGLynparza 100 mg film-coated tablets
DRUGLynparza 150 mg film-coated tablets
Sponsors
Azienda Ospedaliero Universitaria Di Modena
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR), defined as the percentage of patients with response of either CR or PR. | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of PFS (progression-free survival), DOR (duration of response), DCR (disease control rate), OS (overall survival), safety and tolerability of treatment. Furthermore, the quality of life will be assessed through the EORTC QLQ-C30 questionnaire. | — |
Countries
Italy
Outcome results
None listed